{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T14:29:03Z","timestamp":1791815343761,"version":"4.3.4"},"reference-count":56,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","labmed.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Laboratory Medicine"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.cll.2016.07.004","type":"journal-article","created":{"date-parts":[[2016,9,2]],"date-time":"2016-09-02T11:19:08Z","timestamp":1472815148000},"page":"777-793","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Use of the Clinical Laboratory in Psychiatric Practice"],"prefix":"10.1016","volume":"36","author":[{"given":"Christopher","family":"Aloezos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Wai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin H.","family":"Bluth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Forman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.cll.2016.07.004_bib1","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0736-4679(99)00101-8","article-title":"The use of lithium levels in the emergency department","volume":"17","author":"Sadosty","year":"1999","journal-title":"J\u00a0Emerg Med"},{"issue":"1","key":"10.1016\/j.cll.2016.07.004_bib2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1053\/ajem.2001.20003","article-title":"Drug screening versus history in detection of substance use in ED psychiatric patients","volume":"19","author":"Perrone","year":"2001","journal-title":"Am J Emerg Med"},{"issue":"5","key":"10.1016\/j.cll.2016.07.004_bib3","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/j.1360-0443.2006.01397.x","article-title":"Declared and undeclared substance use among emergency department patients: a population-based study","volume":"101","author":"Rockett","year":"2006","journal-title":"Addiction"},{"issue":"4","key":"10.1016\/j.cll.2016.07.004_bib4","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1176\/appi.ps.51.4.474","article-title":"Utility of routine drug screening in a psychiatric emergency setting","volume":"51","author":"Schiller","year":"2000","journal-title":"Psychiatr Serv"},{"issue":"2","key":"10.1016\/j.cll.2016.07.004_bib5","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1017\/S1481803500009064","article-title":"Screening urine for drugs of abuse in the emergency department: do test results affect physicians' patient care decisions?","volume":"6","author":"Eisen","year":"2004","journal-title":"CJEM"},{"issue":"1","key":"10.1016\/j.cll.2016.07.004_bib6","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.psym.2012.08.007","article-title":"Drug screens for psychiatric patients in the emergency department: evaluation and recommendations","volume":"54","author":"Kroll","year":"2013","journal-title":"Psychosomatics"},{"issue":"1","key":"10.1016\/j.cll.2016.07.004_bib7","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.annemergmed.2005.10.002","article-title":"Clinical policy: critical issues in the diagnosis and management of the adult psychiatric patient in the emergency department","volume":"47","author":"Lukens","year":"2006","journal-title":"Ann Emerg Med"},{"issue":"1","key":"10.1016\/j.cll.2016.07.004_bib8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1176\/ps.51.1.41","article-title":"The last half-century of psychiatric services as reflected in psychiatric services","volume":"51","author":"Gellar","year":"2000","journal-title":"Psychiatr Serv"},{"issue":"3","key":"10.1016\/j.cll.2016.07.004_bib9","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1037\/0022-006X.68.3.438","article-title":"Relation of the therapeutic alliance with outcome and other variables: a meta-analytic review","volume":"68","author":"Martin","year":"2000","journal-title":"J\u00a0Consult Clin Psychol"},{"key":"10.1016\/j.cll.2016.07.004_bib10","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1176\/ps.49.2.196","article-title":"Compliance with medication regimens for mental and physical disorders","volume":"49","author":"Cramer","year":"1998","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.cll.2016.07.004_bib11","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1192\/bjp.183.3.197","article-title":"Clinical interventions for treatment non-adherence in psychosis: meta-analysis","volume":"183","author":"Nose","year":"2003","journal-title":"Br J Psychiatry"},{"issue":"10","key":"10.1016\/j.cll.2016.07.004_bib12","first-page":"1","article-title":"Practice guideline for the treatment of patients with major depressive disorder third edition","volume":"167","author":"Gelenberg","year":"2010","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.cll.2016.07.004_bib13","series-title":"Stahl\u2019s essential psychopharmacology. The prescriber\u2019s guide","author":"Stahl","year":"2011"},{"key":"10.1016\/j.cll.2016.07.004_bib14","series-title":"Handbook of psychiatric drug therapy","author":"Labbate","year":"2009"},{"issue":"5","key":"10.1016\/j.cll.2016.07.004_bib15","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/sj.mp.4001494","article-title":"Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response","volume":"9","author":"Kirchheiner","year":"2004","journal-title":"Mol Psychiatry"},{"issue":"2","key":"10.1016\/j.cll.2016.07.004_bib16","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1176\/ajp.153.2.151","article-title":"Initiation and adaptation: a paradigm for understanding psychotropic drug action","volume":"153","author":"Hyman","year":"1996","journal-title":"Am J Psychiatry"},{"issue":"10","key":"10.1016\/j.cll.2016.07.004_bib17","doi-asserted-by":"crossref","first-page":"712","DOI":"10.4088\/JCP.v61n1002","article-title":"How fast are antidepressants?","volume":"61","author":"Gelenberg","year":"2000","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"4","key":"10.1016\/j.cll.2016.07.004_bib18","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1136\/emj.18.4.236","article-title":"Tricyclic antidepressant overdose: a review","volume":"18","author":"Kerr","year":"2001","journal-title":"Emerg Med J"},{"issue":"5","key":"10.1016\/j.cll.2016.07.004_bib19","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/hup.502","article-title":"Long-term efficacy and therapeutic drug monitoring of sertraline in major depression","volume":"18","author":"Mauri","year":"2003","journal-title":"Hum Psychopharmacol"},{"issue":"2","key":"10.1016\/j.cll.2016.07.004_bib20","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/00007691-200004000-00011","article-title":"Venlafaxine serum levels and CYP2D6 genotype","volume":"22","author":"Veefkind","year":"2000","journal-title":"Ther Drug Monit"},{"issue":"7","key":"10.1016\/j.cll.2016.07.004_bib21","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1176\/ajp.154.7.963","article-title":"Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study","volume":"154","author":"Amsterdam","year":"1997","journal-title":"Am J Psychiatry"},{"issue":"5770","key":"10.1016\/j.cll.2016.07.004_bib22","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1136\/bmj.3.5770.331","article-title":"Relationship between plasma level and therapeutic effect of nortriptyline","volume":"3","author":"Asberg","year":"1971","journal-title":"Br Med J"},{"issue":"10","key":"10.1016\/j.cll.2016.07.004_bib23","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0361-1124(79)80408-6","article-title":"Tricyclic antidepressant overdose","volume":"8","author":"Callaham","year":"1979","journal-title":"JACEP"},{"issue":"5","key":"10.1016\/j.cll.2016.07.004_bib24","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/00007691-200310000-00010","article-title":"Routine therapeutic drug monitoring in patients treated with 10-360\u00a0mg\/day citalopram","volume":"25","author":"Le bloc'h","year":"2003","journal-title":"Ther Drug Monit"},{"issue":"5","key":"10.1016\/j.cll.2016.07.004_bib25","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1034\/j.1600-0447.2000.101005354.x","article-title":"Therapeutic drug monitoring of selective serotonin reuptake inhibitors influences clinical dosing strategies and reduces drug costs in depressed elderly patients","volume":"101","author":"Lundmark","year":"2000","journal-title":"Acta Psychiatr Scand"},{"issue":"6","key":"10.1016\/j.cll.2016.07.004_bib26","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0031-1286287","article-title":"AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011","volume":"44","author":"Hiemke","year":"2011","journal-title":"Pharmacopsychiatry"},{"issue":"7215","key":"10.1016\/j.cll.2016.07.004_bib27","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1038\/nature07455","article-title":"The molecular neurobiology of depression","volume":"455","author":"Krishnan","year":"2008","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.cll.2016.07.004_bib28","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1093\/jat\/24.5.340","article-title":"Screening procedure for detection of antidepressants of the selective serotonin reuptake inhibitor type and their metabolites in urine as part of a modified systematic toxicological analysis procedure using gas chromatography-mass spectrometry","volume":"24","author":"Maurer","year":"2000","journal-title":"J\u00a0Anal Toxicol"},{"issue":"10","key":"10.1016\/j.cll.2016.07.004_bib29","doi-asserted-by":"crossref","first-page":"349","DOI":"10.5694\/j.1326-5377.1949.tb36912.x","article-title":"Lithium salts in the treatment of psychotic excitement","volume":"2","author":"Cade","year":"1949","journal-title":"Med J Aust"},{"issue":"3","key":"10.1016\/j.cll.2016.07.004_bib30","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/0092-8674(89)90026-3","article-title":"Neural and developmental actions of lithium: a unifying hypothesis","volume":"59","author":"Berridge","year":"1989","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.cll.2016.07.004_bib31","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0960-9822(02)70790-2","article-title":"Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in Intact cells","volume":"6","author":"Stambolic","year":"1996","journal-title":"Curr Biol"},{"issue":"22","key":"10.1016\/j.cll.2016.07.004_bib32","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJM198911303212201","article-title":"Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder","volume":"321","author":"Gelenberg","year":"1989","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.cll.2016.07.004_bib33","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.1994.03510360044034","article-title":"Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group","volume":"271","author":"Bowden","year":"1994","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.cll.2016.07.004_bib34","doi-asserted-by":"crossref","first-page":"478","DOI":"10.4088\/JCP.v65n0405","article-title":"A\u00a0multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes","volume":"65","author":"Weisler","year":"2004","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"4","key":"10.1016\/j.cll.2016.07.004_bib35","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1001\/archpsyc.60.4.392","article-title":"A\u00a0placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder","volume":"60","author":"Bowden","year":"2003","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"10.1016\/j.cll.2016.07.004_bib36","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.eurpsy.2004.11.003","article-title":"Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies","volume":"20","author":"Abi-Dargham","year":"2005","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.cll.2016.07.004_bib37","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1176\/ajp.153.12.1579","article-title":"Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges","volume":"153","author":"VanderZwaag","year":"1996","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.cll.2016.07.004_bib38","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/jat\/32.2.147","article-title":"Quantitation of seven low dosage antipsychotic drugs in human post mortem blood using LC-MS-MS","volume":"32","author":"Roman","year":"2008","journal-title":"J\u00a0Anal Toxicol"},{"key":"10.1016\/j.cll.2016.07.004_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s002139900333","article-title":"Predicting haloperidol occupancy of central dopamine D2 receptors from plasma levels","volume":"149","author":"Fitzgerald","year":"2000","journal-title":"Psychopharmacology (Berl)"},{"issue":"3","key":"10.1016\/j.cll.2016.07.004_bib40","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2165\/00003088-199834030-00005","article-title":"The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia","volume":"34","author":"Ulrich","year":"1998","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10.1016\/j.cll.2016.07.004_bib41","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/00004714-200004000-00010","article-title":"Pharmacologic profile of perphenazine\u2019s metabolites","volume":"20","author":"Robinson","year":"2000","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.cll.2016.07.004_bib42","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/00004714-199712000-00007","article-title":"Risperidone dose and blood level variability: accumulation effects and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting","volume":"17","author":"Darby","year":"1997","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.cll.2016.07.004_bib43","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1176\/ajp.156.6.869","article-title":"Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients","volume":"156","author":"Nyberg","year":"1999","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.cll.2016.07.004_bib44","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2174\/1381612023396654","article-title":"Cognitive and sedative effects of benzodiazepine use","volume":"8","author":"Buffett-Jerrott","year":"2002","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.cll.2016.07.004_bib45","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1176\/appi.ps.54.10.1395","article-title":"Benzodiazepine use and abuse among patients with severe mental illness and co-occurring substance use disorders","volume":"54","author":"Brunette","year":"2003","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.cll.2016.07.004_bib46","first-page":"447","article-title":"Therapeutic and toxic blood concentrations of more than 800 drugs and other zenobiotics","volume":"58","author":"Schulz","year":"2003","journal-title":"Pharmazie"},{"key":"10.1016\/j.cll.2016.07.004_bib47","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/jps.2600680119","article-title":"Pharmacokinetics and bioavailability of intravenous, intramuscular, and oral lorazepam in humans","volume":"68","author":"Greenblatt","year":"1979","journal-title":"J\u00a0Pharm Sci"},{"issue":"1","key":"10.1016\/j.cll.2016.07.004_bib48","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4065\/83.1.66","article-title":"Urine drug screening: practical guide for clinicians","volume":"83","author":"Moeller","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.cll.2016.07.004_bib49","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.biopsych.2004.10.020","article-title":"Attention-deficit\/hyperactivity disorder: a selective overview","volume":"57","author":"Biederman","year":"2005","journal-title":"Biol Psychiatry"},{"issue":"12","key":"10.1016\/j.cll.2016.07.004_bib50","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/archpsyc.56.12.1073","article-title":"A\u00a014-month randomized clinical trial of treatment strategies for attention-deficit\/hyperactivity disorder. The MTA Cooperative Group. Multimodal treatment study of children with ADHD","volume":"56","year":"1999","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"10.1016\/j.cll.2016.07.004_bib51","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1542\/peds.104.2.e20","article-title":"Pharmacotherapy of attention-deficit\/hyperactivity disorder reduces risk for substance use disorder","volume":"104","author":"Biederman","year":"1999","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.cll.2016.07.004_bib52","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jpainsymman.2003.07.008","article-title":"Urine drug testing in pain medicine","volume":"27","author":"Heit","year":"2004","journal-title":"J\u00a0Pain Symptom Manage"},{"issue":"1","key":"10.1016\/j.cll.2016.07.004_bib53","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jsat.2014.07.006","article-title":"Misuse of atypical antipsychotics in conjunction with alcohol and other drugs of abuse","volume":"48","author":"Malekshahi","year":"2015","journal-title":"J\u00a0Subst Abuse Treat"},{"issue":"3","key":"10.1016\/j.cll.2016.07.004_bib54","first-page":"216","article-title":"Intravenous bupropion: a previously undocumented method of abuse of a commonly prescribed antidepressant agent","volume":"7","author":"Baribeau","year":"2013","journal-title":"J\u00a0Addict Med"},{"issue":"6","key":"10.1016\/j.cll.2016.07.004_bib55","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1097\/JCP.0b013e3181c09475","article-title":"Abuse potential of bupropion nasal insufflation: a case report","volume":"29","author":"Langguth","year":"2009","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"3","key":"10.1016\/j.cll.2016.07.004_bib56","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1177\/026988119901300321","article-title":"Do antidepressants have any potential to cause addiction?","volume":"13","author":"Haddad","year":"1999","journal-title":"J\u00a0Psychopharmacol"}],"container-title":["Clinics in Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271216300609?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271216300609?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T18:34:14Z","timestamp":1601058854000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272271216300609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S0272271216300609"],"URL":"https:\/\/doi.org\/10.1016\/j.cll.2016.07.004","relation":{},"ISSN":["0272-2712"],"issn-type":[{"value":"0272-2712","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of the Clinical Laboratory in Psychiatric Practice","name":"articletitle","label":"Article Title"},{"value":"Clinics in Laboratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cll.2016.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}